Fulcrum Therapeutics, Inc.
FULCNASDAQHealthcare● Active
$3.44
$-0.25(-6.78%)
Market Cap$186143140
P/E Ratio—
52W High$15.74
52W Low$2.83
Fulcrum Therapeutics, Inc. (FULC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FULC · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.08B | $0.00B | $0.01B | $0.02B |
| Cost of Revenue | $0.00B | $0.06B | $0.00B | $0.08B | $0.07B |
| Gross Profit | ($0.00B) | $0.02B | $0.00B | ($0.07B) | ($0.05B) |
| Gross Margin %(computed) | — | 20.77% | 100.00% | — | -263.73% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.06B | $0.07B | $0.08B | $0.07B |
| G&A Expenses | $0.03B | $0.03B | $0.04B | $0.04B | $0.03B |
| Total Operating Expenses | $0.08B | $0.04B | $0.11B | $0.04B | $0.03B |
| Operating Income | ($0.08B) | ($0.02B) | ($0.11B) | ($0.11B) | ($0.08B) |
| Operating Margin %(computed) | — | -27.37% | — | — | -422.97% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.01B) | ($0.10B) | ($0.11B) | ($0.08B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.01B) | ($0.10B) | ($0.11B) | ($0.08B) |
| Net Margin %(computed) | — | -12.16% | — | — | -421.89% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.18 | $-0.16 | $-1.59 | $-2.35 | $-2.22 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.04B | 0.04B |
| EBITDA | ($0.07B) | ($0.02B) | ($0.11B) | ($0.11B) | ($0.08B) |
| EBITDA Margin %(computed) | — | -22.80% | — | — | -409.85% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Fulcrum Therapeutics, Inc. data
About Fulcrum Therapeutics, Inc. (FULC) Income Statement
Fulcrum Therapeutics, Inc. (FULC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FULC reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.07B) — a net profit margin of —.
Frequently asked questions
FULC · 4 questionsFulcrum Therapeutics, Inc. (FULC) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
FULC revenueFULC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08